Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research

Diabetes and Vascular Disease Research

Volumn 10, Issue 1, 2013, Pages 72-77

  Irace, Concetta ^a   De Luca, Simona ^a   Shehaj, Ermal ^a   Carallo, Claudio ^a   Loprete, Antonio ^a   Scavelli, Faustina ^a   Gnasso, Agostino ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

endothelial function; Exenatide; flow mediated dilation; shear rate; type 2 diabetes; ultrasound

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; FEMALE; FLOW MEDIATED DILATION TECHNIQUE; FOREARM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIMB ISCHEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PREVALENCE; TIME; TREATMENT DURATION; ULTRASOUND; VASCULAR ENDOTHELIUM;

AGED; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; RECEPTORS, GLUCAGON; SULFONYLUREA COMPOUNDS; ULTRASONOGRAPHY, DOPPLER; VASODILATION; VENOMS;

EID: 84871825708     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112449562     Document Type: Article

References (24)

1. De Fronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 ; 28: 1092-1100 (Pubitemid 40616618)
2. Buse JB, Henry RR, Han J, et al. for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin 4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2628-2635 (Pubitemid 39441462)
3. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and sulfonylurea. Diabetes Care. 2005 ; 28: 1083-1091 (Pubitemid 40616617)
4. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 ; 87: 1409-1439 (Pubitemid 350041474)
5. Nyström T, Gutniak MK, Zhang Q, et al. Effect of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004 ; 287: E1209 - E1215
6. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005 ; 54: 146-151 (Pubitemid 40105106)
7. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004 ; 109: 962-965 (Pubitemid 38282847)
8. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilation of the brachial artery. J Am Coll Cardiol. 2002 ; 39: 257-265
9. Calles-Escadon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev. 2001 ; 22: 36-52 (Pubitemid 32187802)
10. Widlansky ME, Gocke N, Keaney JF, et al. The clinical implication of endothelial dysfunction. J Am Coll Cardiol. 2003 ; 42: 1149-1160
11. Black MA, Cable NT, Thijssen DH, et al. Importance of measuring the time course of flow-mediated dilation in humans. Hypertension. 2008 ; 51: 203-211
12. Irace C, Tschakovsky ME, Carallo C, et al. Endothelial dysfunction or dysfunctions? Identification of three different FMD responses in males with type 2 diabetes. Atherosclerosis. 2008 ; 200: 439-445
13. Padilla J, Johnson BD, Newcomer SC, et al. Adjusting flow-mediated dilation for shear stress stimulus allows demonstration of endothelial dysfunction in a population with moderate cardiovascular risk. J Vasc Res. 2009 ; 46: 592-600
14. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow mediated dilatation: Implication for the assessment of endothelial function. J Physiol. 2005 ; 568: 357-369 (Pubitemid 41555444)
15. DeFronzo RA, Ratner RE, Han J, et al. Effect of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005 ; 28: 1092-1100 (Pubitemid 40616618)
16. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006 ; 8: 436-447 (Pubitemid 44349236)
17. Koska J, Schwartz EA, Mullin MP, et al. Improvement of post-prandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent onset type 2 diabetes. Diabetes Care. 2010 ; 33: 1028-1030
18. Thijssen DHJ, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2010 ; 300: H2 - H12
19. Van Poppel PCM, Netea MG, Smits P, et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011 ; 34: 2072-2077
20. Erdogdu O, Nathanson D, Sjoholm A, et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA-, and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010 ; 325: 26-35
21. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: Dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007 ; 293: E1289 - E1295
22. Irace C, Fiorentino R, Carallo C, et al. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 3 diabetes. Diabetes Technol Ther. 2011 2011 ; 13: 1261-1263
23. Ceriello A, Esposito K, Testa R, et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide 1 in diabetes. Diabetes Care. 2011 ; 34: 697-702
24. Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol. 2011 ; 666: 251-256